NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient dosing and screening in its Phase 3 trials of nex-z, citing a serious ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

High-rolling investors have positioned themselves bearish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today through ...

CRISPR powers everything from gene editing to rapid diagnostics, but how did one of its most versatile branches arise? A new Cell study, “Functional RNA splitting drove the evolutionary emergence of ...